Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) expects 120 million yuan to 180 million yuan in attributable loss for 2025, swinging from a profit of 39.7 million yuan in 2024, according to a Hong Kong bourse filing Friday.
Shares of the biomedicine firm fell over 4% in late-morning trade Monday.
The company's financial results are due in late March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.